Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 10INDUSTRY 2UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 13Other solid neoplasm 6Head & Neck 4Breast 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Sarcoma 2

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × Sarcoma × Clear all
NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
99 enrolled 10 charts
Sarcoma

Sarcoma

NCT04074564 2023-10-23

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase EARLY_PHASE1 Unknown
60 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡